Cipla Limited
NSE Symbol CIPLA
CIPLA LIMITED has declared lack lustre results in Qtr ending December 2010.
Net Sales is Rs. 1501.36 cr – down by 4.97% from Q2 FY 11; up by 5.18% from Q1 FY 11; Up by 13.96% from Q4 FY 10; up by 11.7% from Q3 FY 10.
Total Expenditure is Rs.1300.74 cr – down by 0.91% from Q2 FY 11; UP by 9.86% from Q1 FY 11; up by 11.54% from Q4 FY 10; and UP by 17.79% from Q3 FY 10.
Profit from Operations is Rs.252.93 cr – down by 16.43% from Q2 FY 11; down by 14.49% from Q1 FY 11; Up by 21.3% from Q4 FY 10; and down by 24.32% from Q3 FY 10.
Profit before tax is Rs.275.69 cr – down by 13.58% from Q2 FY 11; down by 11.76% from Q1 FY 11; down by 20.81% from Q4 FY 10; down by 20.71% from Q3 FY 10.
Net Profit is Rs.232.69 cr – down by 11.53% from Q2 FY11; down by 9.61% from Q1 FY11; down by 15.55% from Q4 FY 10; down by 19.49% from Q3 FY 10.
Basic EPS is Rs.2.9 – against Rs.3.27 in Q2 FY 11; Rs.3.21 in Q1 FY 11; Rs.3.43 in Q4 FY10; and Rs.3.6 in Q3 FY 10.
Stand Alone Results Table :
| CIPLA | 31-Dec-10 | 30-Sep-10 | 30-Jun-10 | 31-Mar-10 | 31-Dec-09 |
| Net Sales | 150136 | 157988 | 142738 | 131749 | 134416 |
| Net Sales | 150136 | -4.97 | 5.18 | 13.96 | 11.7 |
| Other Oprtg Income | 5231 | 3547 | 5238 | 5720 | 9434 |
| Incr./decr. in SIT / WIP | -6635 | 3972 | 2086 | -8872 | -3279 |
| Raw Materials | 57426 | 53841 | 52247 | 56612 | 47025 |
| Traded Goods | 18793 | 17057 | 12690 | 13342 | 18729 |
| Employees Cost | 13509 | 13758 | 13756 | 9986 | 8895 |
| Depreciation | 6525 | 6391 | 5482 | 4948 | 4567 |
| Other Expenditure | 40456 | 36251 | 32137 | 40602 | 34492 |
| Total Expenditure | 130074 | 131270 | 118398 | 116618 | 110429 |
| Total Expenditure | 130074 | -0.91 | 9.86 | 11.54 | 17.79 |
| Profit from Operations | 25293 | 30265 | 29578 | 20851 | 33421 |
| Profit from Operations | 25293 | -16.43 | -14.49 | 21.3 | -24.32 |
| Other Income5 | 2569 | 1664 | 1675 | 4508 | 1784 |
| Interest6 | 293 | 28 | 11 | 46 | 437 |
| Exceptional Items7 | - | - | - | -9500 | - |
| Profit before tax | 27569 | 31901 | 31242 | 34813 | 34768 |
| Profit before tax | 27569 | -13.58 | -11.76 | -20.81 | -20.71 |
| Tax expense | 4300 | 5600 | 5500 | 7260 | 5865 |
| Net Profit | 23269 | 26301 | 25742 | 27553 | 28903 |
| Net Profit | 23269 | -11.53 | -9.61 | -15.55 | -19.49 |
| Face Value (In Rs | 2 | 2 | 2 | 2 | 2 |
| Paid Up Equity | 16058 | 16058 | 16058 | 16058 | 16058 |
| Basic EPS | 2.9 | 3.27 | 3.21 | 3.43 | 3.6 |
| Public Holding (%) | 62.6 | 62.43 | 62.4 | 62.38 | 62.34 |
ANNOUNCEMENTS
TO NSE
04-02-2011 Cipla Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 150136 lacs for quarter ending on 31-DEC-2010 against Rs. 134416 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 23269 lacs for the quarter ending on 31-DEC-2010 against Rs. 28903 lacs for the quarter ending on 31-DEC-2009.
28-12-2010 Cipla Limited has informed the Exchange about fresh notices received from National Pharmaceutical Pricing Authority, Government of India. The Company has now received further demand notices from the Government demanding an amount of Rs. 47.70 crores in respect of the drug Salbutamol and an amount of Rs. 25.46 crores in respect of the drug Ciprofloxacin. These demands are contrary to the orders of the Hon'ble Supreme Court of India and the Company has received legal advice that entire amounts demanded by the Government are not tenable and sustainable.
11-11-2010 Cipla Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 157988 lacs for quarter ending on 30-SEP-2010 against Rs. 137118 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 26301 lacs for the quarter ending on 30-SEP-2010 against Rs. 27574 lacs for the quarter ending on 30-SEP-2009.
25-08-2010 Cipla Limited has informed the Exchange that the Board of Director of the Company at its meeting held on August 25, 2010, inter alia, has approved the acquisition of Meditab Specialties Pvt. Ltd. ("Meditab") for an aggregate consideration of Rs.133.35 crores.
13-08-2010 Cipla Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 142738 lacs for quarter ending on 30-JUN-2010 against Rs. 132526 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 25742 lacs for the quarter ending on 30-JUN-2010 against Rs. 24171 lacs for the quarter ending on 30-JUN-2009.
24-05-2010 Cipla Limited has informed the Exchange that the Company has set up a Wholly Owned Subsidiary 'Cipla Singapore Pte Limited' in Singapore. The subsidiary has been set up inter-alia to aid logistics and distribution of Company's export business.
* * * E N D * * *
No comments:
Post a Comment